全球阿茲海默症生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

阿茲海默症生物標記市場預計將從 2025 年的 15.9 億美元成長到 2034 年的 35.6 億美元，2026 年至 2034 年的複合年成長率為 9.35%。

由於阿茲海默症和其他神經退化性疾病的盛行率不斷上升，全球阿茲海默症生物標記市場正在成長。全球人口老化是推動早期精準診斷需求的主要因素。生物標記在疾病早期檢測中發揮著至關重要的作用，有助於制定更有效的治療方案和疾病管理。對早期診斷日益成長的關注正在推動市場成長。

神經病學領域的研究和開發活動正在加速新產物標記的發現。影像技術、腦脊髓液檢測和血液生物標記檢測等方面的技術進步提高了診斷的準確性。政府對失智症研究的資助和支持也促進了市場擴張。製藥公司在藥物研發和臨床試驗中越來越依賴生物標記。

未來幾年，無創且經濟高效的診斷測試的發展預計將惠及市場。基於血液的生物標記因其便利性而備受關注。人們對大腦健康的日益重視以及對個人化醫療投入的增加將進一步推動市場需求。隨著阿茲海默症新治療方法的出現，生物標記檢測將變得更加重要。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球阿茲海默症生物標記市場：依生物標記類型分類

• 市場分析、洞察與預測
• 腦脊髓液生物標記
• BETA-澱粉樣蛋白
• Tau蛋白
• 基因生物標記
• 載脂蛋白E
• 血液生物標記
• 其他

第5章 全球阿茲海默症生物標記市場：依檢測技術分類

• 市場分析、洞察與預測
• 分子診斷
• 免疫檢測

第6章 全球阿茲海默症生物標記市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 診斷檢查室
• 研究機構和學術中心
• 其他

第7章 全球阿茲海默症生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Enzo Life Sciences Inc
  • Thermo Fisher Scientific Inc
  • AnaSpec Inc
  • Merck KGaA
  • Cell Signaling Technology Inc
  • Fujirebio
  • Imagilys
  • NanoSomiX
  • QIAGEN
  • 23andMe Inc
  • Quanterix
  • C2N Diagnostics
  • Quest Diagnostics

The Alzheimer's Disease Biomarkers Market size is expected to reach USD 3.56 Billion in 2034 from USD 1.59 Billion (2025) growing at a CAGR of 9.35% during 2026-2034.

The Global Alzheimer's Disease Biomarkers Market is growing due to the increasing prevalence of Alzheimer's disease and other neurodegenerative disorders. The aging global population is a key factor driving the need for early and accurate diagnosis. Biomarkers play an important role in detecting the disease at an early stage, which helps in better treatment planning and disease management. This rising focus on early diagnosis is supporting market growth.

Research and development activities in neurology are accelerating the discovery of new biomarkers. Technological advancements in imaging techniques, cerebrospinal fluid testing, and blood-based biomarker tests are improving diagnostic accuracy. Government funding and support for dementia research are also contributing to market expansion. Pharmaceutical companies are increasingly relying on biomarkers for drug development and clinical trials.

In the coming years, the market is expected to benefit from the development of non-invasive and cost-effective diagnostic tests. Blood-based biomarkers are likely to gain significant attention due to their convenience. Growing awareness about brain health and increasing investments in personalized medicine will further boost demand. As new therapies for Alzheimer's emerge, biomarker testing will become even more essential.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Of Biomarker

• CSF Biomarkers
• Amyloid Beta
• Tau Protein
• Genetic Biomarkers
• Apolipoprotein E
• Blood Biomarkers
• Others

By Detection Technique

• Molecular Diagnostics
• Immunoassays

By End-User

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes and Academic Centers
• Others

COMPANIES PROFILED

• Enzo Life Sciences Inc, Thermo Fisher Scientific Inc, AnaSpec Inc, Merck KGaA, Cell Signaling Technology Inc, Fujirebio, Imagilys, NanoSomiX, QIAGEN, 23andMe Inc, Quanterix, C2N Diagnostics, Quest Diagnostics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY TYPE OF BIOMARKER 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Biomarker
• 4.2. CSF Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Amyloid Beta Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Tau Protein Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Genetic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Apolipoprotein E Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Blood Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY DETECTION TECHNIQUE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Detection Technique
• 5.2. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunoassays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Research Institutes and Academic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ALZHEIMER'S DISEASE BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Biomarker
  • 7.2.2 By Detection Technique
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Biomarker
  • 7.3.2 By Detection Technique
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Biomarker
  • 7.4.2 By Detection Technique
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Biomarker
  • 7.5.2 By Detection Technique
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Biomarker
  • 7.6.2 By Detection Technique
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ALZHEIMER'S DISEASE BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Enzo Life Sciences Inc
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 AnaSpec Inc
  • 9.2.4 Merck KGaA
  • 9.2.5 Cell Signaling Technology Inc
  • 9.2.6 Fujirebio
  • 9.2.7 Imagilys
  • 9.2.8 NanoSomiX
  • 9.2.9 QIAGEN
  • 9.2.10 23andMe Inc
  • 9.2.11 Quanterix
  • 9.2.12 C2N Diagnostics
  • 9.2.13 Quest Diagnostics